Longwall Ventures

What they fund

Longwall funds early-stage UK science and engineering companies, with a focus on sectors including advanced manufacturing, clean energy, defence, and life sciences [2]. They back complex challenges that require complex solutions in complex markets, specifically targeting hard science origins [1]. The firm provides patient capital and technical fluency for deep, emergent technology, understanding that great science does not emerge from the lab market-ready and requires a journey from prototype to product [1]. They back ideas that other investors underestimate, focusing on the difficult transition from early research to global business [1].

Investment thesis

Longwall Ventures is an early venture capital firm focused on UK deeptech, turning research into enduring businesses since 2008. They back complex challenges requiring complex solutions in complex markets, specifically targeting hard science origins [1]. The firm provides patient capital and technical fluency for deep, emergent technology, understanding that great science does not emerge from the lab market-ready and requires a journey from prototype to product [1]. They back ideas that other investors underestimate, focusing on the difficult transition from early research to global business [1].

Credibility: The firm's website explicitly outlines this thesis, emphasizing their role as deeptech specialists who help transform UK research into global businesses [1].

Value add

Longwall acts as a partner that gets stuck in from day one, building patiently and deliberately [1]. They talk to customers and avoid over-engineering, providing hands-on and collaborative support [1]. They bring decades of experience to building global businesses out of hard science [1].

Fit verdict: Ideal for founders with hard science origins who need patient capital and technical fluency to navigate the journey from prototype to product.

Founder diligence script:

• How does Longwall's technical fluency specifically apply to my deep, emergent technology?
• What is Longwall's track record in helping companies transition from prototype to product?
• How does Longwall's patient capital approach align with my company's timeline to market?
• What is Longwall's strategy for helping companies scale globally from the UK?

Portfolio focus

The portfolio spans more than 50 companies across medical devices, aerospace, and defence applications [2]. Notable companies include Oxford Space Systems, which leverages textile knitting techniques and origami to design high-performance antennas for next-generation satellite constellations [1]. Lightcast Discovery focuses on programmable single-cell analysis on a massive scale [1]. Wayland Additive provides innovative metal additive manufacturing for stronger, lighter, and more complex parts [1]. Caristo Diagnostics predicts heart attack risk by detecting invisible coronary inflammation from a standard CT angiogram [1].

Notable investments & exits

Longwall was an early investor in OrganOx, which was sold to Terumo Corporation in 2025 for over $1.5 billion, delivering a 19.2x return for Longwall's investors [2].

Strategic implications

Longwall's focus on UK deeptech and its anchor from the British Business Bank positions it as a key player in the UK's scientific and engineering innovation ecosystem. The firm's patient capital approach and technical fluency are critical for deep, emergent technology companies that require a long journey from prototype to product. Longwall's track record of successful exits, such as OrganOx, demonstrates its ability to build global businesses out of hard science.

Where they could go further

Longwall could expand its geographic focus beyond the UK to attract more international deeptech companies. The firm could increase its check size range to support later-stage funding rounds for its portfolio companies. Longwall could develop more co-investment opportunities with other deeptech-focused funds to share risk and expertise.